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Although the only effective drug against primary hepatocarcinoma, the multikinase inhibitor Sorafenib
(SFB) usually fails to eradicate liver cancer. Since SFB targets mitochondria, cell metabolic reprogramming
may underlie intrinsic tumor resistance. To characterize cancer cell metabolic response to SFB, wemeasured
oxygen consumption, generation of reactive oxygen species (ROS) and ATP content in rat LCSC (Liver
Cancer Stem Cells) -2 cells exposed to the drug. Genome wide analysis of gene expression was performed by
Affymetrix technology. SFB cytotoxicity was evaluated by multiple assays in the presence or absence of
metabolic inhibitors, or in cells genetically depleted of mitochondria. We found that low concentrations
(2.5–5 mM) of SFB had a relatively modest effect on LCSC-2 or 293 T cell growth, but damaged
mitochondria and increased intracellular ROS. Gene expression profiling of SFB-treated cells was consistent
with a shift toward aerobic glycolysis and, accordingly, SFB cytotoxicity was dramatically increased by
glucose withdrawal or the glycolytic inhibitor 2-DG. Under metabolic stress, activation of the AMP
dependent Protein Kinase (AMPK), but not ROS blockade, protected cells from death. We conclude that
mitochondrial damage andROSdrive cell killing by SFB, while glycolytic cell reprogrammingmay represent
a resistance strategy potentially targetable by combination therapies.
A
erobic glycolysis (‘‘Warburg effect’’) represents one of the distinctive tracts (‘‘hallmarks’’) of themalignant
phenotype1–4. Although energetically less efficient than respiration, fermentative metabolism is advant-
ageous for cell growth due to the increased availability of anabolic intermediates and the reduced cell
dependence on oxygen; moreover, by increasing intracellular reducing equivalents (NADPH and glutathione)
and decreasing mitochondria-derived ROS, glycolysis protects malignant cells from oxidant-induced senescence
and apoptosis5 and contributes to the survival of Cancer Stem Cell (CSC)6. Biochemical differences between
cancerous and normal cellsmay help directing targeted therapies againstmalignant elements. For instance, tumor
cells are often strongly dependent on glucose (‘‘glucose-addicted’’) and therefore exquisitely sensitive to the
glycolytic inhibitor 2-deoxyglucose (2DG)7. Notably, the link between metabolism, oxidative stress and cancer
may be particularly relevant to the liver8, that plays a pivotal role in the regulation of glucose homeostasis. Hence
liver cancer cells, like the hepatocholangiocarcinoma cell line LCSC-2 we’ve recently derived from a novel model
of carcinogenesis in rats9, appear ideally suited to investigate biochemical mechanisms and therapeutic implica-
tions of cancer cell metabolic reprogramming.
Themultikinase inhibitor Sorafenib (SFB) (Nexavar, BAY43-9006) currently represents the primary treatment
option for advanced hepatocellular carcinoma10; SFB preferentially inhibits the cancer- associated V600Emutant
of the serine-threonine kinase and Ras-effector BRAF, while the wild type enzyme is paradoxically activated by
the drug in the presence of active Ras signaling11; SFB also targets, at concentrations in the high nanomolar range,
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Vascular Endothelial Growth Factor-2 (VEGFR-2), and Vascular
Endothelial Growth Factor-2 (VEGFR-3)12. However, additional
mechanisms likely contributeto the elevated anticancer activity of
this compound, and may have by extension a role in the frequent
emergence of specific chemoresistance13.
Initial evidence point to mitochondrial damage and oxidative
stress as additional, kinase-independent mechanisms underlying cell
response to Sorafenib. In normal cardiomyocytes, for instance, SFB
was reported to inhibit mitochondrial respiration and to decrease
intracellular ATP levels14. Along similar lines, SFB has been shown to
increase the production of mitochondrial ROS (mROS), decrease
reduced Glutathione levels (GSH) and induce cell death in HepG2
human hepatoma cells15, and serum levels of advanced oxidation
protein products in Sorafenib-treated HCC patients correlate with
clinical effectiveness of the drug16. Additionally, in human pancreatic
cell lines SFB elicits MEK/ERK independent apoptosis, through the
downregulation of the mitochondrial antiapoptotic protein Mcl-117.
Prompted by these evidence and by the emerging interest towards
metabolism-targeted anticancer therapies, we sought to investigate
the effect of Sorafenib on mitochondrial activity and oxidative meta-
bolism in rat hepatocolangiocrcinoma LCSC-2 cells, in search for
novel mechanisms of response and/or resistance of liver cancer cells
to this increasingly used drug.
Results
Sorafenib increases intracellular ROS and inhibits respiration in
LCSC-2 cells. Sensitivity of tumor cell lines to RTKs inhibitors is
highly variable, in part depending on the mutational status of RAS
and RAF family members18. Exposure of rat hepatocolangiocarcinoma
LCSC-2 cells, that lack B-RAF activating mutations, to SFB had a
modest growth inhibitory effect as assessed by Propidium Iodide
(PI) exclusion or colony formation assay (Fig. 1, a, b and c),
especially in the presence of fetal bovine serum: in fact, unlike
reported for higly sensitive cell lines12, 50% inhibition was attained
in the low micromolar, rather than nanomolar range. Of note, in this
range no obvious reduction of phosphorylated (active) ERK and
AkT, was observed under cell stimulation with Hepatocyte growth
Factor (HGF), suggesting a growth inhibitory mechanism distinct
from RTK or ERK blockade (Fig. 1, d).
Consistent with previous reports15,16, flow cytometry analysis of cells
loaded with the redox-sensitive dye H2-DCF-DA revealed a marked
and dose dependent increase of ROS 12 hours after exposure to 2,5 or
5 mM SFB (Fig. 1 e and 1 g); LCSC-2 cells often appeared distributed
in two distinct subpopulation peaks based on DCF-DA fluorescence
intensity, both of which were shifted to the right (increased oxidation)
upon exposure to the drug (Fig. 1e). Importantly, the pro-oxidant
effect of SFB was cancelled by the cell permeant hydrogen peroxide
scavenger and GPX mimetic Ebselen (EBS) (Fig. 1 f).
Since mitochondria represent the main sources of ROS in normal
and in tumor cells, we reasoned that ROS increase may reflect an effect
of SFB on these organelles. Accordingly, baseline oxygen consumption
(routine respiration) measured by High Resolution Respirometry was
significantly reduced after 12 hours incubation with SFB, compared to
untreated controls (Fig. 2 a), and a similar difference was observed
under maximum electron flow, as elicited by the mitochondrial pro-
tonophore Carbonyl cyanide p-(tri-fluoromethoxy) phenyl-hydrazone
(FCCP), (Fig. 2 b).
In order to address whether SFB acts directly onmitochondria, we
isolated the organelles from rat liver and assessed their transmem-
brane potential in the presence of the drug, using the cationic fluor-
escent dye JC-1 followed by flow cytometry. As shown in Fig. 2, c,
SFB was able to depolarize mitochondria in vitro, as revealed by an
evident reduction of JC-1 fluorescence in the FL2 (red) channel.
Taken together, these findings confirm that in LCSC-2 cells, as in
other cell models, SFB interferes with mitochondrial function, and
suggest that this effect is due, at least in part, to a direct interaction of
the drug with the organelle.
Sorafenib affects energy metabolism of LCSC2 cells. To further
characterize the impact of SFB on cellular energy metabolism, we
first measured intracellular ATP after twelve hours cell exposure to
the drug. ATP levels were markedly reduced (.50%) in SFB-treated
cells compared to untreated controls (Fig. 3 a), indicating that LCSC-2
cells actively utilize mitochondria for their energy supply. In keeping
with the above finding, SFB elicited the phosphorylation on Threonine
172 of the AMP activated protein kinase (AMPK), an energy sensor
that detects changes in the intracellular AMP/ATP and triggers
metabolic cell adaptations aimed at restoring ATP levels at expense
of anabolic processes (Fig. 3 b). SFB phosphorylation of AMPK was
potentiated by the glycolytic inhibitor 2DG (Fig. 3 c and Supplementary
Figure S5), and was not inhibited by Ebselen (Fig. 3 c), although AMPK
activation may in some contexts respond to ROS19.
To gain insight in the global metabolic cell response to Sorafenib, we
performed microarray analysis of gene expression. A total of 322 dif-
ferentially-expressed genes with $1,5 fold change were identified in
LCSC-2 exposed to the drug. Among these, 174 genes resulted up-
regulated and 148 genes were down-regulated in LCSC-2 treated with
SFB compared to untreated controls (data accessible at http://www.
ncbi.nlm.nih.gov/geo/ under the ID number GSE43053). Of note, mono-
saccaride metabolism (p 5 0.00462) and cell proliferation (p 5
0.00631) were among the highest ranking biological processes enriched
for differently expressed genes (Supplementary Fig. S1 on line).
We focused on genes involved in glucose metabolism. Interestingly,
the expression of three genes directly involved in glycolysis [the solute
carrier family 2 (slc2a3), Enolase 2 (eno2), and the platelet phospho-
fructokinase (pfkp)], was significantly induced by SFB (Fig. 3 d); con-
versely, SFB decreased the expression of acquaporin 9 (aqp9), member
of a family of water-selective membrane channels, and of the mi-
tochondrial enzyme pyruvate dehydrogenase (lipoamide) alpha 1
(pdha1), which catalyzes the irreversible conversion of pyruvate to
acetyl-CoA, thus linking aerobic glycolysis with the tricarboxylic acid
(TCA) cycle in mitochondria. Differences in the expression levels of
selected genes were further validated by quantitative real time PCR
(qPCR) (Fig. 3 e). Moreover, consistent with metabolic shift towards
glycolysis in response to SFB, suggested by the above transcriptional
changes, we observed enhanced uptake of the fluorescent glucose
analog 6NDBG, and increased glucose consumption and L-lactate
release by LCSC-2 cells exposed to the drug (Fig. 3 f, g and h).
Sorafenib toxicity is increased by the glycolytic inhibitor 2-deoxy-
glucose. The above findings propted us to test whether the effects of
SFB could be enhanced by a glycolysis inhibitor, such as the non-
metabolizable glucose analogue 2-deoxy-glucose (2DG).
In toxicity assays (PI exclusion and MTT), 2DG dramatically
increased cell killing by SFB both in LCSC-2 cells (Fig. 4 a and b)
and in the highly malignant murine melanoma cell line B16F10
(Fig. 4 c); a similar effect was elicited by glucose withdrawal from
the culture medium (Supplementary Fig. S2 on line). Of note, the
MEK inhibitor PD98059 had marginal effects on LCSC-2 cells, that
was not enhanced by glucose withdrawal (Supplementary Fig S2 on
line). Instead, in B16F10 cells, the effect of Sorafenib was mimicked
by the mitochondrial Complex I inhibitor Rotenone20 (Fig. 4 c);
moreover, depletion of mitochondrial DNA in a HEK293 cell line
variant expressing a doxycycline inducible dominant negative mutant
of the mitochondrial DNA polymerase gamma 1 (POLG1 D890N)21
nearly abrogated sensitivity to SFB (fig. 4d), further pointing to a
mitochondrial action of the drug. The synergistic effect of SFB and
2DG for cell killing was also confirmed in a number of additional
human and murine cancer cell lines, including Ras-transformed
Mouse Embryonic Fibroblasts (MEF) lacking p53 (Supplementary
Fig. S3 on line).
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AMPK links metabolic damage by SFB to the mTOR/autophagy
cascade. To further characterize the biochemical events elicited
by SFB and its combination with 2DG, we interrogated nutrient
signalling events along the AMPK kinase pathway. In LCSC2 (Fig. 5
a and Supplementary Fig. S5) and B16F10 cells (Supplementary Fig.
S4) SFB and 2DG combinatorially and dose-dependently increased the
phosphorylation of AMPK on Ser 172, consistent with profound cell
de-energization. Even more dramatically the combination inhibited
the phosphorylation of the ribosomal S6 protein, a downstream
effector of the mTOR (mammalian Target of Rapamycin)/S6 Kinase
cascade that is negatively regulated by AMPK under nutrient
deprivation22. Moreover, Similar studies performed on HEK293-
POLG1 (D890N) cells showed that AMPK phosphorylation by SFB
is favoured under glycolysis blockade by either 2DG or glucose
deprivation, and that it requires active mitochondria, as indicated by
the lack of response to the drug (or the presence of an opposite,
inhibitory action) in mtDNA-depleted cells (Fig. 5 d).
Noticeably, as an additional output of AMPK/mTOR signalling
modulation in LCSC2 cells, SFB and SFB 1 2DG triggered cell autop-
hagy, a self-eating process aimed at cell survival under starvation23;
this was revealed, biochemically, by increased LC3B electrophoretic
mobility (due to covalent conjugation of this phagosome-associated
protein with phosphatidyl-ethanolamine), and degradation of the
autophagy substrate p62 (Fig. 5 a and Supplementary Fig. S5), and,
functionally, by an accelerated autophagic flux (i.e. autophagosome-
autolysosome transition), monitored by confocal analysis of LCSC-2
cells transiently transfected with a mRFP-GFP tandem fluorescent-
tagged LC324 (Fig. 5 b and 5 c).
Figure 1 | Growth inhibition and generation of ROS in LCSC-2 cells exposed to Sorafenib. (a), (b) and (c) Propidium Iodide exclusion assay (a) and
colony formation assay (b and c) showing dose and time-dependent growth-inhibitory effect of SFB on LCSC-2 cells. FCS 5 fetal calf serum. In b, bars
represent plating efficiency (nu colonies/nu of plated cells); c:representative picture of colonies stained with Giemsa. In a and b bars are mean 6 SD of
duplicate or triplicate samples. Panels representative of several independent experiments. (d). Western Blot analysis of Akt (Ser 473) and p44-42 MAP
Kinase (ERK,Thr202/Tyr204) phosphorylation after 12 hours incubation with the indicated combinations of Hepatocyte Growth factor (HGF,
50 ng/ml) and SFB. Anti total ERK immune-staining confirms equal protein loading throughout the lanes. Relevant bands are indicated by arrows.
(e). Representative flow cytometry plot revealing broad distribution of H2-DCFDA fluorescence in LCSC-2 cells and increased signal (oxidation) in
response to 2.5 or 5 mM SFB. (f). Effect of antioxidants and GPX mimetic Ebselen on SFB-induced ROS. A shift of cell fluorescence profile to the left
confirms effective ROS scavenging by the compound. Plots representative of several independent analyses. (g). Quantitation of ROS increase in LCSC-2
cells exposed to 2.5 mM SFB for 12 hours. Values are Mean 6 SD of mean fluorescence ratios (SFB/Dmso) over n 5 6 independent experiments. p
calculated on raw fluorescence values by paired two-tailed t-test.
www.nature.com/scientificreports
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LCSC-2 cell killing by SFB involves ROS and is counteracted by
AMPK. In order to clarify themechanistic role of ROS and phospho-
AMPK, both elicited by SFB, in the cytotoxic activity of the drug, we
first evaluated killing efficiency in LCSC2 cells pre-treated with the
ROS scavenger Ebselen. The antioxidant significantly reduced cell
death in the presence of 5 and 10 mM SFB (p , 0.01) (Fig. 6 a and
Supplementary Fig. 6) confirming SFB-induced oxidative damage as
a necessary contributor to the drug cytotoxic action. Accordingly,
when LCSC-2 with high and low baseline levels of ROS (as revealed
by the fluorescent dye DCF-DA) were separated by fluorescence-
activated cell sorting, the two population displayed different sensiti-
vity (sensitive the former, resistant the latter) to the drug (Fig. 6 b and
c). Interestingly, however, Ebselen had no effect on massive cell killing
by the SFB 1 2DG combination (Fig. 6A and Supplementary Fig. 6),
implying a ROS independent toxic mechanisms (energy depletion?)
for the latter synergistic effect. On the other hand, AMPK depletion by
siRNA technology (Fig. 6 d and e) potentiated cell killing by 5 mMSFB
both alone and in combination with 2DG (p , 0.05 and p , 0.01,
respectively), in parallel with impaired inhibition of mTOR/S6K
signaling (Fig. 6 e). A cell protective role for AMPK in response to
SFB was further corroborated by pharmacological modulation of
the kinase with the cell permeant activator 5-Aminoimidazole-4-
carboxamide 1-b-D-ribofuranoside (AICAR, 5 mM, p , 0.05),
and the specific inhibitor Compound C (20 mM, p , 0.01). Thus,
AMPK activation likely contributes to resistance to Sorafenib at least
in LCSC-2 cells.
Discussion
Cancer cell metabolism relies on a delicate balance between the
glycolytic pathway, considerably amplified to provide for the needs
of a rapid and invasive growth, and oxidative phosphorylation,
which remains active, to contribute to the tumor energy needs1,25.
Interference with this unique metabolic setting may open new pos-
sibilities for targeted anticancer therapy.
We have here investigated the metabolic effects of Sorafenib, a
multikinase inhibitor, reported to preferentially target mutant
(V600E) BRAF and a number of cancer-relevant tyrosine kinase
receptors12. These effects, that include inhibition of mitochondrial
respiration, reduced ATP production, and elevation of intracellular
ROS, are in many cell lines, including the rat hepatocolangiocarci-
noma cell line LCSC-2, largely insufficient to drive cell death; we here
suggest that such ineffectiveness is due, to an efficient cell reprogram-
ming towards aerobic glycolysis. The dramatic increase of SFB cyto-
toxicity by glucose withdrawal or the glycolytic inhibitor 2DG clearly
supports this view, opening to the possibility of employing SFB in
novel metabolism-based combination therapies. Importantly, SFB
potentiation by glycolysis blockade was not limited to liver-derived
cells, but also extended to melanoma cells and other cell types, and is
Figure 2 | Sorafenib inhibits cellular respiration and depolarizes isolatedmitochondria. (a) and (b). Respirometric Analysis of LCSC-2 cells exposed for
2, 6 and 12 hours to 2.5 mM SFB or Dmso as vehicle control. The two histograms illustrate the inhibitory effect of the drug on Routine Respiration (A),
and uncoupled respiration (B) (see methods for experimental details). Asterisks denote statistical significance (two-tailed Student t-test, compared to
untreated control). (c). Flow cytometry analysis of mitochondrial staining with the potentiometric dye JC-1. Decreased red (FL-2) fluorescence of
mitochondria exposed to SFB indicates loss of trans-membrane potential (y). Plot representative of two independent experiments.
www.nature.com/scientificreports
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likely to be independent from the tumor suppressor p53 (Supple-
mentary Fig. S3).
Noteworthy, signaling studies (Fig. 1 d) indicate that metabolic
actions of Sorafenib are independent from inhibition of RTK signal-
ing, suggesting instead a direct interaction of the compound with
mitochondria. Since mitochondria represent a novel promising sub-
strate for targeted drugs26, molecular interactions of SFB with this
organelle certainly deserve to be further investigated.
In keeping with the idea that SFB metabolically reprograms target
cells, microarray data are consistent with a cell shift towards aerobic
glycolysis, with a significant up-regulation of genes involved in the
glycolytic pathway, such as scl2a3 (also known as GLUT-3, a glucose
transporter27), pfkp (Phosphofructokinase, platelet isoform28) and
eno2 (Enolase 2, a part of the phosphopyruvate hydratase complex29)
(Supplementary Fig. S1). Importantly, all these three genes have been
previously linked to human malignancy30–32. Conversely, among
SFB-downregulated genes related to metabolism, the mitochondrial
enzyme pyruvate dehydrogenase (lipoamide) alpha 1 (pdha1) cata-
lyzes the irreversible conversion of pyruvate to acetyl-CoA, linking
the glycolysis with the tricarboxylic acid (TCA) cycle and respira-
tion33. Thus, overall, this gene signature points to a glycolytic adapt-
ive response to mitochondrial failure, as it is also consistent with
evidence of enhanced glucose consumption and lactate production
in SFB-treated LCSC-2 cells (Fig. 3D).
Glycolysis provides, beside ATP and anabolic intermediates, also
reducing equivalents (through the Pentose Phosphate Pathway, PPP)
that maintain the GSH/GSSG redox buffer, and increased glycolysis
may counteract SFB action, in part, by improving the cell antioxidant
capacity34. In support of this view, LCSC-2 cells with constitutively
low levels of ROS are intrinsically resistant, unlike cells with high
ROS, to the drug action (Fig. 6 b and c). Interestingly, a similar Low-
ROS profile identifies putative stem cells from normal and tumor
breast cancer cell populations6, suggesting the possibility that resist-
ance to SFB and a low oxidant content characterizes a subset LCSC-2
of cells with the properties of Cancer Stem Cells. By extension, res-
istance of CSC to SFB may explain the limited curative capacity of
Figure 3 | Sorafenib modulates energy metabolism. (a). ATP measurement in LCSC-2 cells treated with SFB. Values are in light units normalized for
protein content. Bars are Mean 6 SD of duplicate sample. Statistics are by two-tailed t-test. Histogram representative of two independent experiments.
(b). Immunodetection of phospho-(Thr 172) AMPK phosphorylation under the indicated stimuli; anti AMPK (total) immunoblotting was used as
loading control. (c). Anti p-AMPK immunoblot showing no inhibitory effect of Ebselen on AMPK phosphorylation by SFB or SFB 1 2DG. Total AMPK
was used as loading control. Relevant bands are indicated by arrows. Picture representative of at least two independent experiments. Black colums are
Mean6 SDof densitometric values from2–3 independent experiments, normalized for average band indesity. (d). Glycolysis-related genesmodulated by
Sorafenib in LCSC-2 cells. Fold change refers to the untreated (Dmso) sample. Upregulated genes are highlighted in red, downregulated genes in green.
(e). Real Time PCR validation of three selected genes from panel C, a. Fold change (SFB/Dmso) for each gene was calculated by the DCt method
(see SupplementaryMethods); bars aremean6 SDof three independent reactions. Statistics are by two-tailed t-test. (f), (g) and (h). Bar graphs displaying
enhanced 6NBDG uptake and increased glucose metabolism in LCSC-2 cells after 48 hours exposure to SFB. Bars are Mean SD of 2–3 independent
samples. * p , 0.05 (ANOVA); *** p , 0.0001 (t-test).
www.nature.com/scientificreports
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this drug10.With this respect it is noteworthy that glycolysis blockade
overcomes SFB resistance in fashion that is ROS-independent (Fig. 6
a and Supplementary Fig. 6) and therefore circumvents, unlike SFB
alone, potential antioxidants-based survival strategies implemented
by cancer (stem) cells.
LCSC-2 resistance to Sorafenib also involves AMP kinase. Dose
dependent induction of AMPK phosphorylation by SFB is most
likely a consequence of cell de-energization, and appears to be inde-
pendent of ROS (fig. 3 c) but requires active mitochondria, as shown
by lack of response inHEK-293 cells grown in high glucose or devoid
ofmitochondrial DNAby a POLG1 dominant negativemutant (fig. 5
e and Supplementary Fig. S5). Moreover, a protective role for the
kinase against SFB-induced cell death is strongly suggested by experi-
ments of genetic and pharmacologic inhibition of the enzyme (fig. 6
d–f) and by correlative evidence of constitutive AMPK phosphoryla-
tion and resistance to SFB in HEK-293T POLG1 D890N cells (figs. 4
d, 5e and Supplemntary Fig. S5). Multiple protective mechanisms,
including downregulation of mTOR signaling with reduced ATP
consumption35, induction of autophagy (fig. 5 b and c), and genetic
reprogramming (Supplementary Fig. S1) may account for this effect.
While this aspect needs to be further clarified, the above observations
are translationally relevant to the possibility of targeting AMPK in
combination with SFB to increase cell response to the drug. Moreover,
similar to other mitochondria-targeting drugs like Biguanides, tumor
sensitivity to SFB may be predicted by loss of function of the tumor
suppressor and AMPK activating kinase LKB136, and boosted by lim-
ited glucose availability in the tumor mass37. Of note, while this manu-
script was in preparation, it was reported that SFB antitumor action is
mediated by AMPK/mTOR in breast cancer cells38, indicating that
roles of AMPK downstream of this drug may be tumor- and context-
dependent.
In conclusion, we have here provided novel evidence for import-
ant metabolic effects of the multikinase inhibitor Sorafenib on liver
cancer cells. Our observations, althoughwith the intrinsic limitations
Figure 4 | Sorafenib toxicity is increased by the glycolytic inhibitor 2-deoxy-glucose. (a). Cytotoxic effect of SFB (5 mM) and 2DG (20 mM), applied as
single agents or in combination, in LCSC-2 cells. Percentage of dead (Propidium Iodide-permeant) cells was determined by flow cytometry after 24 hours
exposure to the drugs. The dashed line indicates the expected value for simple additivity, cleared of background cell death (Dmso), calculated by the
Bliss Independence Model (see Supplementary Methods). A white circle in the SFB 1 2DG bar indicates the amount of cell death entirely attributable to
the drug combination, cleared of the background. ** indicates p , 0.01 compared to vehicle; interaction denotes a significant ‘‘cell (row 3 column)
effect’’ in the two-way ANOVA test. Histogram representative of several independent experiments (b).MTTAssay under the same conditions as in a. Bars
are mean 6 SD of three independent experiments, each in duplicate. Line and statistics are as in panel a. (c). Evaluation of SFB toxicity and SFB 1 2DG
interaction in B16mousemelanoma cells. Cells were analysed for PI exclusion as in a, after 24 hours exposure to the drugs. Rotenone (Rot, 5 mM),mimics
the effect of SFB (2.5 mM), and synergizes with 2DG. Bars are mean 6 SD of duplicate samples. * 5 p , 0.05 and ** 5 p , 0.01 compared to Dmso.
Statistics as in panel a. Panel representative of two independent experiments. (d)MTT assay showing lack of response to SFB (5 mM) ofHEK293 –POLG1
(D890N) cells grown in doxycycline 50 ng/ml for 10 days to deplete mtDNA (Dox1); Dox- are non-induced cells that retain mtDNA. Picture
representative of two independent experiments. Statistics as in panel a.
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of studies in vitro, indicate in mitochondria an important target of
the drug’s action, involve ROS in SFB-dependent cytotoxicity, and
identify multiple (AMPK, metabolic reprogramming, antioxidant
capacity) potential mechanisms of drug resistance, to be circum-
vented by novel and more effective combination therapies.
Methods
Reagents and antibodies.Most of the Chemicals were obtained from Sigma-Aldrich
(Milan, Italy). Sorafenib (Nexavar, BAY 43-9006) was kindly provided by Bayer
Pharmaceuticals. Antibodies and siRNA are listed in SI.
Plasmids. ptfLC3 (mRFP-GFP tandem fluorescent-tagged LC3) was a gift from
Tamotsu Yoshimori (Addgene plasmid # 21074).
Cell lines and transfections.The rat hepatocholangiocarcinoma cell line LCSC-2was
kindly provided by Dr. Thomas D. Shupe and Dr. Bryon E. Petersen (Dept. of
Pathology, University of Florida, Gainesville, FL). Cells were maintained in
Dulbecco’s modified Eagle medium (DMEM 4.5 g/L d-glucose)/Ham’s F12 medium
50550, supplemented with 8% FBS and 1% antibiotics (LCSC-medium). Flp-InTM T-
RExTM HEK-293 cells stably expressing the D890N dominant negative mutant of the
mitochondrial Polymerase gamma (POLG1) under a Tetracycline-inducible
promoter have been previously described21. Cell were routinely maintained in
standard DMEM (4.5 g/L d-glucose). Induction of the recombinant POLG1-myc
protein was readily detectable after 24 hours treatment with 50 ng/ml Doxycycline
(Sigma), and was maintained for 10 days in order to severely deplete mitochondrial
DNA. Additional cell lines are described in SI.
Transfection of cDNA and siRNA into LCSC-2 cells was performed with
LipofectamineH 2000 (Life Technologies) and HiPerFect (QIAGEN), respectively,
according to the manufacturer’s recommendations.
Cytotoxicity assays. ForMTT assay, cells were seeded in 24-well plates (23 105/well)
or 96 well plates (5 3 104/well) and challenged with SFB other stimuli in serum-free
medium.
After 24 hours of incubation MTT solution (1510 dilution of the 5 mg/ml stock)
was added to cells and incubated at 37uC for three additional hours. The MTT-
Figure 5 | AMPK linksmetabolic damage by SFB to themTOR/autophagy cascade. (a).Western blot analysis of protein lysates from LCSC-2 stimulated
for 4–6 hours with the indicated combinations of SFB and 2DG. Phosphorylation of AMP (Ser 172) and of the mTOR effector S6 (Ser 235/236) were
monitored by phospho-specific antibodies. Total AMPK is also displayed. In the lowest two panels, appearance of a fast migrating LC3B band (LC3B II)
and decreased anti-p62 signal in SFB and SFB 1 2DG treated samples denote enhanced autophagy. Picture representative of three independent
experiments with comparable results. (b). Confocal analysis of LCSC-2 cells transiently transfected with a tandem red-green flurescent tagged LC3 and
exposed to SFB for 6 hours. Red puncta (autolysosomes) and yellow puncta (autophagosomes) were counted and the ratio calculated for each cell. a. Bars
aremean6 SD of n5 51 (Dmso) and n5 32 (SFB); statistics by t-test. (c). representative fluorescentmicrophotographs displaying enhanced autophagic
flux (prevalence of red over yellow dots) in the sample exposed to SFB. (d). Expression of myc-tagged POLG1 (D890N) in HEK293 cells ten days after
cultivation in the presence of 50 ng/ml doxycyclin. (e). Induced (Dox1) and non induced (Dox2) HEK-293 POLG1 (D890N) cells were stimulated for
4 hours as indicated (SFB 1 5 5 mM) and phosphorylation of AMPK and S6 evaluated by immunoblotting as in a. Total AMPK is also depicted.
In the latter panel, appearance of a faint slowmigrating band above themain one confirms AMPKhyperphosphorylation. SFB has little effect onAMPK in
this highly glycolytic cell line, unless glycolysis is inhibited (2DG and No Glucose). Mitochondria depletion cancels SFB stimulatory effect on AMPK.
www.nature.com/scientificreports
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containing mediumwas then removed, and the converted dye solubilized with 500 ml
(24 well plate) or 100 ml (96 well plate) of acidic isopropanol (0.04 MHCl in absolute
isopropanol or Isopropanol/Dmso 151 v/v. Absorbance was read at 570 nm.
For Propidium Iodide exclusion assay, medium containing floating cells was
removed and attached cells were trypsinized and pooled with the floating ones in flow
cytometry test tubes. Few seconds after addition of Propidium Iodide (1 mg/ml final
concentration) cells were analysed for red fluorescence by flow cytometry (Exc.
488 nm, red fluorescence channel FL-3). Percentage of PI positive (dead) cells was
determined, after exclusion of cell debris.
Colony formation assay
For the determination of the colony formation capability, cells were seeded in 6-well
plates (500/well) in complete culture medium. After two weeks cells were fixed with
3,7% Formalin for five hours and stained with 0.02% Giemsa.
Intracellular ATPmeasurement. For intracellular ATP detection, cells were seeded in 12
well plates (43 105/well/ml) in presence or in absence of relevant stimuli. After 12 h cells
were processed and ATP was detected by using Promega kit, ENLITENH ATP Assay
System Bioluminescence Detection, according to the provider’s recommendations39.
High resolution respirometry on intact cells. A suspension of LCSC-2 in DMEM/
F12, processed respectively with DMSO (ctrl) and Sorafenib 2.5 mM, was added to
each Oxygraph Chamber (Chamber A and Chamber B), at a density of 0.5 3
106 cells/ml.
The experiments began with the measurement of the Routine respiration
(i.e. the respiration of drug-treated cells resuspended in the medium without
the addiction of substrates), followed for about 10 minutes (STATE R). Then,
2 ml of 4 mg/ml Oligomycin, an ATP synthase blocker, were added in each
chamber (STATE L) and respiration was recorded for 6 minutes.
Subsequently, 5 mg/ml of FCCP (a protonophore - H1 ionophore - and
uncoupler of oxidative phosphorylation) were added (STATE E) and res-
piration was recorded for 3 minutes; higher FCCP concentrations or wider/
broader time intervals exert an inhibitory effect on cellular respiration
depending on mitochondria.
All inhibitors and uncouplers used in the protocol are able to cross the cell mem-
brane and do not require a prior cells permeabilization40.
Confocal analysis of autophagic flux in LCSC-2 cells. Quantitative assessment of
autophagosome to-autolysosome maturation dynamic the was performed according
to24 using a fluorescent tagged LC3 probe.
Figure 6 | LCSC-2 cell killing by SFB involves ROS and is counteracted byAMPK. (a) PI exclusion assay depicting the effect of Ebselen (2 mM, gray bars)
on LCSC-2 cell growth inhibition by SFB and SFB 1 2DG. Bars are mean 6 SD of duplicate or triplicate samples. Statistics are by two-way ANOVA.
** p , 0.01 compared to vehicle. Significance for the interaction SFBxEBS is also indicated. Representative of two independent experiments.
(b). Identification and sorting of LCSC-2 cell populations with low and high content of ROS, based on H2-DCFDA fluorescence distribution on green
fluorescence FL-1 histogram. (c). growth inhibition evaluated by MTT assay. Values are percentages of Dmso/PBS. Bars are mean 6 SD of duplicate
samples. Statistics of relevant comparisons by two-way ANOVA are indicated. Significance for the interaction effect (ROS x SFB) is indicated. Picture
representative of two independent experiments. (d). Knock-down of AMPKa by siRNA sensitizes LCSC-2 cells to SFB. (e). PI exclusion assay on
mock (siCtrl) and AMPK-silenced (siAMPKa) LCSC-2 cells exposed to SFB alone or in combination with 2DG for 24 hours. Significant differences
(AMPK versus Ctrl) are indicated by asterisks. * p , 0.05; **p , 0.01 by two-way ANOVA. Bars are mean 6 SD of duplicate samples. Picture
representative of two independent experiments. (e). western blot analysis confirming AMPK downregulation and impaired pS6 inhibition/LC3B
lipidation in siAMPK-treated cells exposed to SFB. Representative of two independent experiments. (f). PI exclusion assay illustrating LCSC-2 sensitivity
to 5 mMSFB upon pharmacological modulation of AMPKa; inhibitors were added to cells 2 hours prior to SFB, and viability was assessed 22 hour later.
* p , 0.05 ** p , 0.01 by one-way ANOVA. Values are mean 6 SD of duplicate samples. Picture representative of two independent experiments.
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Isolation of mitochondria from rat liver.Mitochondria were isolated from the liver
of an adult femaleWistar rat, using the kit MITOISO1 from Sigma. Determination of
organelle transmembrane potential with JC-1 was performed according to the kit
instructions, as described elsewhere41.
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